Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum
30/12/2025 13:33
Dec 30 (Reuters) - InflaRx NV IF0G.F: INFLARX PROVIDES UPDATE ON PHASE 3 DATA ANALYSES FOR VILOBELIMAB IN PYODERMA GANGRENOSUM INFLARX NV - PHASE 3 TRIAL OF VILOBELIMAB TERMINATED DUE TO FUTILITY INFLARX NV: ANTICIPATES MEETING WITH FDA TO DETERMINE A POTENTIAL DEVELOPMENT PATH FORWARD IN PG INFLARX: SUBSEQUENT POST-HOC ANALYSES SUGGEST POSITIVE TREND IN FAVOR OF VILOBELIMAB, WITH SIGNALS INDICATING POTENTIALLY CONSISTENT TREATMENT EFFECT Source text: ID:nGNXkzKjQ Further company coverage: IF0G.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum